

Rogelio Apiquian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1268534/publications.pdf>

Version: 2024-02-01

32
papers

550
citations

623734

14
h-index

642732

23
g-index

33
all docs

33
docs citations

33
times ranked

767
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuropsychological screening with TOWI: Performance in 6- to 12-year-old children. <i>Applied Neuropsychology: Child</i> , 2022, 11, 115-124.	1.4	3
2	Similarities and Differences in Associations Between Duration of Untreated Psychosis (DUP) and Demographic, Premorbid, and Symptom Severity Measures in Two Samples of First-Episode Psychosis Patients from Mexico and the United States. <i>Psychiatric Quarterly</i> , 2020, 91, 769-781.	2.1	5
3	Standardization and validity of Chefmania, a video game designed as a cognitive screening test for children. <i>Humanities and Social Sciences Communications</i> , 2020, 7, .	2.9	4
4	Perception of non-imputability in schizophrenia in adolescents of Mexico City. <i>Spanish Journal of Legal Medicine</i> , 2019, 45, 48-51.	0.2	0
5	Cognitive impairment and its improvement after six months in adolescents with schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2019, 17, 100135.	1.3	4
6	Effectiveness of a treatment guideline for schizophrenia in adolescents: Lessons from a middle-income country. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 192-199.	2.3	2
7	A video game for the neuropsychological screening of children. <i>Entertainment Computing</i> , 2017, 20, 1-9.	2.9	11
8	Validity and reliability of the Spanish version of the Personal and Social Performance scale in adolescents with schizophrenia. <i>Schizophrenia Research</i> , 2015, 164, 176-180.	2.0	6
9	Registro Electrónico de Adherencia al Tratamiento de Esquizofrenia en Latinoamérica (e-STAR): Resultados clínicos del uso de risperidona inyectable de liberación prolongada a dos años de seguimiento. <i>Salud Mental</i> , 2013, 36, 19.	0.3	1
10	Association study of DRD3 gene in schizophrenia in Mexican sib-pairs. <i>Psychiatry Research</i> , 2011, 190, 367-368.	3.3	4
11	Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 7, 19.	2.2	12
12	Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia. <i>Schizophrenia Research</i> , 2009, 112, 181-186.	2.0	36
13	APOE-Îµ3 and APOE-219G Haplotypes Increase the Risk for Schizophrenia in Sibling Pairs. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009, 21, 440-444.	1.8	7
14	Variations of rest-activity rhythm and sleep-awake in schizophrenic patients versus healthy subjects: An actigraphic comparative study. <i>Biological Rhythm Research</i> , 2008, 39, 69-78.	0.9	18
15	Association analysis of exon III and exon I polymorphisms of the dopamine D4 receptor locus in Mexican psychotic patients. <i>Psychiatry Research</i> , 2007, 153, 209-215.	3.3	14
16	Temperament and character in violent schizophrenic patients. <i>Schizophrenia Research</i> , 2007, 94, 74-80.	2.0	28
17	The P50 auditory evoked potential in violent and non-violent patients with schizophrenia. <i>Schizophrenia Research</i> , 2007, 97, 128-136.	2.0	17
18	Association Study of MAO-A and DRD4 Genes in Schizophrenic Patients with Aggressive Behavior. <i>Neuropsychobiology</i> , 2007, 55, 171-175.	1.9	37

#	ARTICLE	IF	CITATIONS
19	The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study. <i>BMC Psychiatry</i> , 2005, 5, 22.	2.6	10
20	Violent behavior in schizophrenic patients: relationship with clinical symptoms. <i>Aggressive Behavior</i> , 2005, 31, 511-520.	2.4	41
21	Amoxapine as an Atypical Antipsychotic: A Comparative Study Vs Risperidone. <i>Neuropsychopharmacology</i> , 2005, 30, 2236-2244.	5.4	28
22	Frontal and limbic metabolic differences in subjects selected according to genetic variation of the SLC6A4 gene polymorphism. <i>NeuroImage</i> , 2005, 25, 1197-1204.	4.2	40
23	A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients. <i>Schizophrenia Research</i> , 2005, 72, 123-129.	2.0	69
24	Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. <i>BMC Psychiatry</i> , 2004, 4, 12.	2.6	19
25	Premorbid adjustment and violent behavior in schizophrenic patients. <i>Schizophrenia Research</i> , 2004, 69, 143-148.	2.0	15
26	Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study. <i>Schizophrenia Research</i> , 2003, 59, 35-39.	2.0	18
27	Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 403-408.	2.1	19
28	The Mexican first-episode psychotic study: clinical characteristics and premorbid adjustment. <i>Schizophrenia Research</i> , 2002, 53, 161-163.	2.0	13
29	Lack of Association of Apolipoprotein E Polymorphism in Obsessive-Compulsive Disorder. <i>CNS Spectrums</i> , 2001, 6, 978-979, 992.	1.2	4
30	Dopamine D4 Receptor (DRD4) Gene Polymorphism in the First Psychotic Episode. <i>Archives of Medical Research</i> , 2001, 32, 35-38.	3.3	10
31	Personality and Clinical Predictors of Recurrence of Depression. <i>Psychiatric Services</i> , 1999, 50, 376-380.	2.0	53
32	Typical antipsychotics: The threshold doses strategy. <i>European Neuropsychopharmacology</i> , 1996, 6, 199.	0.7	2